Table 3. Summary of morbidity and mortality outcomes in patients who underwent stereotactic body radiation therapy for pulmonary metastases.
| Author | 30-day mortality (%) | Acute toxicities and grades | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pneumonitis | Esophagitis | Dyspnea | Erythema | Fatigue | Chest pain | |||||||||||
| Gr 1 | Gr 2 | Gr 3 | Gr 1 | Gr 3 | Gr 1 | Gr 2 | Gr 1 | Gr 2 | Gr 1 | Gr 2 | ||||||
| Francheschini | 0 | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | ||||
| Pasqualetti | 0 | 1 (3%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Agolli | 0 | 2 (4.5%) | 5 (11.4%) | 0 | 1 (2.3%) | 0 | 1 (2.3%) | 0 | 0 | 0 | 0 | 0 | ||||
| Filippi | 0 | 7 (17.5%) | 3 (7.5%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Osti | 0 | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | NS | ||||
| Jingu | 0 | NR | NR | 2 (2.2%) | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Niibe | 0 | NR | NR | 0 | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Yamamoto | 0 | NS | NS | NS | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Takeda | 0 | NS | NS | NS | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Qiu | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Binkley | 0 | 0 | NS | NS | NS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Ricco | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Jung | 0 | 0 | 2 (4%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Kim | 0 | 6 (46%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 (46%) | 0 | |||||
| Thibault | 0 | NS | NS | NS | NR | NR | NR | NR | NR | NR | NR | NR | ||||
| Kinj | 0 | 2 (5.4%) | 2 (5.4%) | 0 | 0 | 0 | 0 | 1 (2.7%) | 10 (27%) | 1 (2.7%) | 1 (2.7%) | 0 | ||||
| Sharma | 0 | 0 | 0 | 0 | 0 | 3 (1.5%) | 0 | 0 | 0 | 0 | 0 | 1 (0.5%) | ||||
| Carvajal | 0 | NR | NR | 0 | NR | NR | NR | NR | NR | NR | NR | NR | ||||
Gr, grade; NR, not reported; NS, not specified.